Atlas Trials

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Clinical trial NCT04981717 · TERMINATED

Trial details

NCT number
NCT04981717
Sponsor
Regeneron Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Allergic Rhinitis Due to Cat Allergy
Start date
2021-07-30
Primary completion
2023-01-04
Enrollment
446

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.